GO:0070628 proteasome binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070628 (proteasome binding) is a molecular function defined as binding to a proteasome, the large multisubunit complex that catalyzes protein degradation.
• Proteasome binding is mediated by dedicated proteasome receptors and shuttle factors that recognize ubiquitin or ubiquitin-like degradation tags and deliver substrates to the 20S/26S proteasome.
• The proteasome is a plastic, ATP-dependent machine whose subunit composition and associated proteins change with cellular state, directly influencing which substrates are bound and degraded.
• Proteasome binding also underlies ubiquitin-independent degradation, in which substrates interact directly with proteasomal subunits without prior polyubiquitination.
• Dysregulated proteasome binding contributes to cancer, neurodegeneration and muscle differentiation defects, making it a tractable target for functional genomics.
• CRISPR knockout, point-mutation, knock-in and overexpression models combined with proteomics and degradation assays are the standard toolkit for dissecting proteasome-binding mechanisms.
Description
GO:0070628, proteasome binding, is a molecular function that describes the physical interaction of a protein with the proteasome, a large multisubunit protein complex that catalyzes protein degradation. This term captures the recognition step that precedes proteolysis: before a substrate can be destroyed, it must first be bound by the proteasome or by a proteasome-associated receptor or shuttle factor. Because the proteasome is the principal route for regulated protein turnover in eukaryotes, the binding events annotated to GO:0070628 sit at the decision point between protein stability and degradation. Researchers study proteasome binding to understand how cells control the half-life of regulatory proteins, how degradation tags are decoded, and how proteasome plasticity reshapes substrate selection under stress or disease conditions. The function is not limited to ubiquitinated substrates; ubiquitin-independent degradation pathways also depend on direct proteasome binding. Recent structural work has revealed how dedicated adaptors such as TXNL1 and midnolin engage the proteasome, expanding the repertoire of proteins annotated to this term. Consequently, GO:0070628 is a central node linking protein quality control, cell-cycle regulation, differentiation and immune surveillance.
proteasome binding At A Glance
| GO ID | GO:0070628 |
|---|---|
| GO term | proteasome binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a proteasome, a large multisubunit protein complex that catalyzes protein degradation |
| Biological context | Protein quality control, regulated proteolysis, ubiquitin-dependent and ubiquitin-independent degradation |
| Representative binders | Proteasome receptors, shuttle factors, and direct substrate proteins such as TXNL1 and midnolin |
| Disease relevance | Cancer, neurodegeneration, muscle differentiation disorders |
| Experimental readouts | Co-immunoprecipitation, pull-down, proximity labeling, structural biology, degradation assays |
What Is GO:0070628?
In our own words, GO:0070628 (proteasome binding) is the molecular function of selectively and non-covalently interacting with a proteasome, the large multisubunit protein complex that catalyzes protein degradation. It covers direct binding to proteasomal subunits as well as binding to proteasome-associated receptors and shuttle factors that physically dock substrates onto the proteasome. The term is agnostic to whether the bound substrate is ubiquitinated, reflecting both ubiquitin-dependent and ubiquitin-independent degradation routes.
Why Is proteasome binding Important in Cell Biology?
Proteasome binding is important because it is the first committed step in regulated protein degradation, determining which proteins are destroyed and when. The proteasome is a plastic complex whose subunit composition and interacting partners change with cellular state, so alterations in proteasome binding can reprogram the entire degradation landscape. This function is essential for cell-cycle progression, differentiation, stress responses and immune surveillance, and its dysregulation is implicated in cancer and neurodegeneration. Understanding proteasome binding therefore provides mechanistic insight into how cells maintain proteostasis and offers targets for therapeutic intervention.
• Controls the selectivity of regulated protein degradation by determining which substrates dock onto the proteasome.
• Enables both ubiquitin-dependent and ubiquitin-independent degradation routes.
• Underpins proteasome plasticity, allowing substrate selection to adapt to cellular state.
• Is required for myoblast differentiation and muscle-specific gene programs.
• Contributes to suppression of myeloma through the midnolin-proteasome pathway.
• Provides structural targets such as TXNL1-bound proteasome interfaces for inhibitor design.
• Links protein quality control to cell-cycle and apoptotic regulation.
• Serves as a functional node for CRISPR screens and proteomics-based target discovery.
• Is altered in neurodegeneration where proteasome capacity and substrate binding decline.
• Offers a measurable phenotype for knockout and knock-in validation studies.
Molecular Mechanism of proteasome binding
Substrate recognition and degradation-tag binding
In simple terms: The proteasome must first grab the protein that is going to be destroyed.
Proteasome binding begins with recognition of a degradation tag or a direct binding motif on the substrate. In the bacterial proteasome, the inter-domain region acts as a selectivity barrier that controls access of degradation-tag-bearing proteins to the catalytic core. In eukaryotes, receptors and shuttle factors recognize ubiquitin or ubiquitin-like tags and deliver the substrate to the proteasome, ensuring that only appropriately tagged proteins are bound. This step is reversible and competitive, allowing cells to prioritize substrates under changing conditions.
Docking to the 20S and 26S proteasome
In simple terms: Once grabbed, the substrate is physically docked onto the proteasome machine.
After recognition, substrates or shuttle factors dock onto the proteasome through specific subunit interfaces. The 26S proteasome comprises a 20S catalytic core and one or two 19S regulatory particles that contain receptors for ubiquitin and for shuttle factors. Structural studies show that adaptors such as TXNL1 bind defined surfaces on the proteasome, illustrating how docking is spatially organized. This docking step positions the substrate for translocation into the catalytic chamber and is a key point of regulation.
Ubiquitin-independent proteasome binding
In simple terms: Some proteins are destroyed without being tagged by ubiquitin first.
Not all proteasome binding requires ubiquitin. Ubiquitin-independent proteasomal degradation occurs when substrates interact directly with proteasomal subunits or with non-ubiquitin adaptors. This route expands the range of proteins annotated to GO:0070628 and explains why some short-lived proteins are degraded even when ubiquitination is blocked. The midnolin-proteasome pathway provides a recent structural example of a dedicated adaptor that engages the proteasome to target specific substrates.
Proteasome plasticity and regulation of binding
In simple terms: The proteasome changes its parts, which changes what it can grab.
Proteasome binding is regulated by proteasome plasticity: the exchange of catalytic and regulatory subunits alters the repertoire of bound substrates. Different proteasome subtypes and associated proteins can favor distinct substrate classes, and post-translational modifications of proteasome subunits modulate binding affinity. This plasticity allows cells to tune degradation capacity during stress, differentiation and immune challenge.
Coupling binding to translocation and catalysis
In simple terms: Binding is only useful if it leads to the protein being pulled in and cut up.
Productive proteasome binding is coupled to ATP-dependent translocation of the substrate into the 20S catalytic chamber, where proteolysis occurs. The 19S regulatory particle uses ATPases to unfold and thread substrates through a narrow pore, and binding must be properly oriented for this to occur. Defects in coupling between binding and translocation can stall degradation and lead to accumulation of undegraded substrates.
Key Genes Involved in GO:0070628 proteasome binding
The following genes and proteins are experimentally linked to proteasome binding, either as proteasome subunits, receptors, shuttle factors or direct substrate adaptors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PSMA1 | 20S core alpha subunit | Structural component of the catalytic core; target for knockout studies of proteasome assembly |
| PSMB5 | 20S core beta subunit with chymotrypsin-like activity | Catalytic subunit; point mutations confer inhibitor resistance |
| PSMC2 | 19S regulatory particle ATPase | Required for substrate unfolding and translocation after binding |
| PSMD1 | 19S regulatory particle non-ATPase subunit | Scaffold for ubiquitin receptors and shuttle factor docking |
| TXNL1 | Thioredoxin-like proteasome-associated protein | Structural basis of TXNL1-bound proteasome recently resolved |
| MIDN | Midnolin, proteasome adaptor | Mediates midnolin-proteasome pathway and myeloma suppression |
| UBB | Ubiquitin B precursor | Provides ubiquitin tags recognized by proteasome receptors |
| UBC | Ubiquitin C | Polyubiquitin source for degradation-tag binding |
| UBQLN1 | Ubiquitin-like shuttle factor | Delivers ubiquitinated substrates to the proteasome |
| UBQLN2 | Ubiquitin-like shuttle factor | Implicated in neurodegeneration and proteasome delivery |
| RAD23A | Ubiquitin-like shuttle factor | Binds ubiquitinated substrates and proteasome |
| RAD23B | Ubiquitin-like shuttle factor | Coordinates nucleotide excision repair and degradation |
| NUB1 | Ubiquitin-like negative regulator | Modulates proteasome binding of specific substrates |
| ID1 | Inhibitor of DNA binding 1 | Proteasome-dependent turnover controls myoblast differentiation |
| PSMD4 | 19S ubiquitin receptor RPN10 | Directly binds polyubiquitin chains at the proteasome |
| ADRM1 | 19S ubiquitin receptor RPN13 | Binds ubiquitin and UCH37 deubiquitinase |
| PSMD14 | 19S deubiquitinase RPN11 | Removes ubiquitin chains during substrate engagement |
How Is proteasome binding Regulated?
Proteasome binding is regulated at multiple levels. Proteasome plasticity, including exchange of catalytic and regulatory subunits, changes the substrate-binding repertoire in response to cellular state. Post-translational modifications of proteasome subunits and associated shuttle factors modulate binding affinity and specificity. The availability of ubiquitin tags and the activity of deubiquitinases at the proteasome further regulate whether a substrate remains bound long enough to be translocated. In differentiation contexts, proteasome-dependent turnover of ID1 is required for myoblast differentiation, showing that binding is developmentally controlled. Recent structural work on TXNL1 and midnolin indicates that dedicated adaptors can impose additional layers of regulation on proteasome engagement.
proteasome binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MIDN | Multiple myeloma suppression | Knockout and overexpression in myeloma cell lines |
| PSMB5 | Proteasome inhibitor resistance in cancer | Point mutation knock-in at catalytic site |
| UBQLN2 | Neurodegeneration and protein aggregation | Knockout and knock-in in neuronal cells |
| ID1 | Myoblast differentiation defects | Knockout and overexpression in myoblast lines |
| TXNL1 | Proteasome-associated redox regulation | Tagged knock-in and knockout for interaction studies |
Cancer and myeloma
Proteasome binding is central to cancer biology because proteasomal degradation controls the abundance of oncoproteins and tumor suppressors. The midnolin-proteasome pathway has been shown to suppress myeloma, and structural characterization of this pathway provides a rationale for targeting adaptor-mediated proteasome binding. Proteasome inhibitors are clinically used in myeloma, and mutations in proteasome subunits that alter binding or catalysis can confer resistance.
Neurodegeneration
Impaired proteasome binding and reduced proteasome capacity contribute to the accumulation of aggregation-prone proteins in neurodegenerative disease. Shuttle factors such as UBQLN2 deliver ubiquitinated substrates to the proteasome, and defects in this delivery system are linked to neuronal dysfunction. Because ubiquitin-independent degradation also depends on proteasome binding, its failure can exacerbate proteotoxic stress.
Muscle differentiation and myogenesis
Proteasome binding regulates myoblast differentiation through the controlled turnover of ID1. When proteasome-dependent degradation of ID1 is perturbed, differentiation programs are disrupted, illustrating how proteasome binding influences developmental decisions. This makes myogenesis a tractable model for studying proteasome binding in a physiological context.
From proteasome binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for proteasome binding? | CRISPR knockout followed by co-immunoprecipitation |
| Does a specific residue mediate proteasome interaction? | Point-mutation knock-in of the candidate residue |
| Does an adaptor domain suffice for proteasome docking? | Knock-in of tagged or truncated adaptor |
| Does overexpression alter substrate degradation? | Doxycycline-inducible overexpression |
| Which substrates depend on a given adaptor? | Knockout plus quantitative proteomics |
| Can a disease variant disrupt proteasome binding? | Patient-derived point-mutation knock-in |
How to Study the proteasome binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction with proteasome subunits | Validation of candidate proteasome binders |
| Pull-down with proteasome subunits | Direct binding to immobilized proteasome proteins | Mapping interaction domains |
| Cryo-electron microscopy | Three-dimensional structure of proteasome-adaptor complexes | Defining binding interfaces |
| Crosslinking mass spectrometry | Proximity of residues within proteasome complexes | Mapping contact sites |
| Cycloheximide chase | Substrate stability over time | Testing degradation dependence on binding |
| Quantitative proteomics | Global changes in proteasome-bound proteins | Identifying substrates and adaptors |
| Proximity labeling | Transient interactions in living cells | Capturing dynamic proteasome binding |
Co-immunoprecipitation and pull-down assays
Co-immunoprecipitation and pull-down assays are the primary methods to detect proteasome binding, using antibodies against proteasome subunits or tagged candidate proteins. These assays can be combined with mass spectrometry to identify the bound proteasome subunits and associated factors. They are typically performed under native conditions to preserve the large multisubunit complex.
Structural biology and crosslinking mass spectrometry
Cryo-electron microscopy and crosslinking mass spectrometry resolve the interfaces through which adaptors such as TXNL1 and midnolin bind the proteasome. These approaches define the molecular contacts required for binding and guide mutagenesis experiments. Structural data also reveal conformational changes in the proteasome upon substrate engagement.
Degradation and stability assays
Cycloheximide chase and pulse-chase assays measure whether proteasome binding leads to substrate degradation. Reporter substrates can be used to quantify degradation rates in knockout or knock-in backgrounds. These functional assays complement binding data by establishing causality.
Proteomics and interactome profiling
Quantitative proteomics after proteasome affinity purification identifies the set of proteins bound to the proteasome under different conditions. Proximity labeling can capture transient proteasome interactions in living cells. Comparative proteomics between wild-type and mutant cells reveals substrates whose degradation depends on a specific binding interface.
How CRISPR Can Be Used to Study GO:0070628 proteasome binding
Knockout
CRISPR knockout of candidate proteasome-binding genes is used to test whether the gene is required for substrate degradation or proteasome assembly. Knockout of ID1 regulators, for example, reveals effects on myoblast differentiation. Knockout followed by co-immunoprecipitation can determine whether a specific adaptor is necessary for proteasome binding.
Point Mutation
Point-mutation knock-in allows precise testing of residues predicted to mediate proteasome binding. Mutating the TXNL1 or midnolin interface can abolish binding without removing the entire protein, providing cleaner mechanistic evidence. Point mutations in proteasome subunits can also model inhibitor resistance observed in cancer.
Knock-in
Tagged knock-in of proteasome subunits or adaptors enables endogenous-level purification and imaging of proteasome binding. Knock-in of disease-associated variants can reveal how mutations alter binding affinity or substrate selection. This approach preserves native regulation, unlike overexpression.
Overexpression
Overexpression of candidate proteasome binders or adaptors can test whether increased dosage alters degradation capacity. Inducible overexpression avoids confounding effects of chronic high-level expression. Overexpression combined with proteomics can identify substrates whose turnover is sensitized to adaptor levels.
How EDITGENE Supports proteasome binding Research
Researchers studying proteasome binding-related genes often need to determine whether a candidate gene is causally involved in substrate recognition, proteasome assembly or degradation. EDITGENE provides the full spectrum of CRISPR cell models and screening services required to move from correlation to mechanism.
Contact EDITGENE today to design your custom CRISPR model for proteasome binding research.
Frequently Asked Questions About proteasome binding
What is GO:0070628 proteasome binding?
GO:0070628 is a molecular function describing binding to a proteasome, the large multisubunit complex that catalyzes protein degradation.
What genes are involved in proteasome binding?
Genes include proteasome subunits such as PSMA1, PSMB5, PSMC2 and PSMD1, adaptors such as TXNL1 and MIDN, and shuttle factors such as UBQLN1, UBQLN2, RAD23A and RAD23B.
How does the proteasome recognize substrates?
Substrates are recognized through ubiquitin or ubiquitin-like degradation tags by proteasome receptors and shuttle factors, or through direct binding motifs in ubiquitin-independent pathways.
Is proteasome binding always ubiquitin-dependent?
No. Ubiquitin-independent proteasomal degradation occurs when substrates bind directly to proteasomal subunits or non-ubiquitin adaptors.
What is proteasome plasticity?
Proteasome plasticity refers to changes in proteasome subunit composition and associated proteins that alter substrate binding and degradation capacity.
Which diseases involve altered proteasome binding?
Cancer, including myeloma, neurodegeneration and muscle differentiation disorders have been linked to altered proteasome binding.
How can I study proteasome binding in the lab?
Common methods include co-immunoprecipitation, pull-down assays, cryo-electron microscopy, crosslinking mass spectrometry and degradation assays.
What is the midnolin-proteasome pathway?
It is a dedicated adaptor pathway in which midnolin engages the proteasome to target specific substrates, with roles in suppressing myeloma.
What is the role of TXNL1 in proteasome binding?
TXNL1 is a thioredoxin-like protein whose structure bound to the proteasome has been resolved, revealing how it docks onto the complex.
Can CRISPR be used to study proteasome binding?
Yes. Knockout, point-mutation, knock-in and overexpression CRISPR models are widely used to test the function of proteasome-binding proteins.
Conclusion
GO:0070628 proteasome binding defines the molecular recognition step that commits proteins to degradation by the proteasome. It encompasses ubiquitin-dependent and ubiquitin-independent routes and is shaped by proteasome plasticity and dedicated adaptors such as TXNL1 and midnolin. Because proteasome binding controls the stability of key regulatory proteins, its dysregulation contributes to cancer, neurodegeneration and differentiation disorders. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with proteomics and structural methods, provide the tools needed to dissect these mechanisms and to identify therapeutic targets.
References
- 1. Gu ZC et al.. 2014. Proteasome assembly.. Cell Mol Life Sci 71(24):4729-45 PMID: 25107634
- 2. Gao J et al.. 2025. Structure of the TXNL1-bound proteasome.. Nat Struct Mol Biol 32(12):2398-2402 PMID: 40770113
- 3. Nardone C et al.. 2025. Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma.. Mol Cell 85(13):2597-2609.e11 PMID: 40532701
- 4. Mor-Rashti Z et al.. 2024. The Bacterial Proteasome Inter-domain Is a Selectivity Barrier for Degradation-tag Binding.. J Mol Biol 436(6):168462 PMID: 38301806
- 5. Erales J et al.. 2014. Ubiquitin-independent proteasomal degradation.. Biochim Biophys Acta 1843(1):216-21 PMID: 23684952
- 6. Glickman MH et al.. 2005. Proteasome plasticity.. FEBS Lett 579(15):3214-23 PMID: 15890341
- 7. Leng X et al.. 2019. Roles of the proteasome and inhibitor of DNA binding 1 protein in myoblast differentiation.. FASEB J 33(6):7403-7416 PMID: 30865843
- 8. Jung T et al.. 2012. Structure of the proteasome.. Prog Mol Biol Transl Sci 109:1-39 PMID: 22727418
